• Mr. Mohammad Faizan Noor Mohammad
• Mr. Karan Amarlal Katariya
• Dr. Neha N Rajpurohit
• Dr. K Raja Rajeshwari

ABSTRACT Three of the most deadly infectious illnesses that threaten global public health, particularly in middle- and low-income nations, are tuberculosis (TB), malaria, and acquired immune deficiency syndrome. TB brought about A third of the world's population contracts tuberculosis (TB), an infectious illness spread by the mycobacterium tuberculosis (Mtb) bacteria that causes around 16 million deaths annually. Drugs for tuberculosis are provided in various combinations of the four first-line medications (rifampicin, isoniazid, pyrazinamide, and ethambutol), which comprise the mainstay of treatment regimens throughout the first six to nine months of treatment. The failure of TB treatment can be attributed to a number of factors, including (i)late Diagnosis, (ii)Evolution of Drug-resistant TB strains. (iii)Long Treatment duration (iv)Lack of timely and proper administration of effective drugs, (v)No adherence to drug regimen (vi)Lower availability of less toxic, inexpensive and effective drugs, Drug-resistant TB presents a serious obstacle to initiatives for TB treatment and control. Given the global context of the 558 000 new cases of TB that developed resistance to rifampicin in 2017—of which 82% developed multidrug-resistant TB (MDR-TB)—it is imperative that our understanding of the processes and molecular underpinnings of Mtb drug resistance be updated on a regular basis. The development of anti-tubercular medications, their mode of action, and treatment resistance mechanisms in multiple myelomavirus (MTB) is summarized in this narrative and traditional review. This review’s objectives are to present current information on drug resistance mechanisms, newly produced or repurposed anti-TB drugs in the pipeline, and global guidelines for managing multidrug-resistant tuberculosis. It attempts to facilitate a better understanding of drug resistance for successful treatment and is based on latest literature and WHO standards. TB therapy and Clinical management.

TB, drug resistance, MTB, WHO, rifampicin

" INFORMATION ON DRUG RESISTANCE TUBERCULOSIS : A SYSTEMIC REVIEW ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 3, page no.f190-f200, March-2024, Available :http://www.jetir.org/papers/JETIR2403524.pdf

" INFORMATION ON DRUG RESISTANCE TUBERCULOSIS : A SYSTEMIC REVIEW ", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 3, page no. ppf190-f200, March-2024, Available at : http://www.jetir.org/papers/JETIR2403524.pdf